Can Median Technologies’ €23.9m boost reshape AI cancer screening in the U.S. and Europe?

Median Technologies (Euronext Growth: ALMDT) has completed a €23.9 million capital increase targeted at institutional and high-net-worth investors, significantly boosting its financial capacity ahead of the U.S. commercial launch of eyonis® Lung Cancer Screening (LCS). The equity raise, finalized on July 30, 2025, will also trigger access to the first €19 million tranche of a previously signed €37.5 million loan agreement with the European Investment Bank (EIB), extending the company’s cash runway through the fourth quarter of 2026.

The oncology-focused software firm structured the raise through the issuance of 14.42 million new ordinary shares with attached warrants, known as ABSA units, priced at €1.66 per unit. Participation in the offering was restricted to investors committing a minimum of €100,000, in compliance with the EU Prospectus Regulation exemptions. This strategic allocation was designed to minimize administrative complexity while attracting long-term backers aligned with the company’s vision in AI-powered medical imaging.

How will Median Technologies deploy the proceeds from its €23.9 million capital increase in 2025?

According to Median Technologies’ leadership, the fresh equity capital will be distributed across three primary initiatives. A portion will directly support the U.S. commercialization of its eyonis® LCS product, which leverages artificial intelligence for early detection of lung cancer. Another segment of funding will accelerate clinical development of eyonis® IPN, designed to identify incidental pulmonary nodules, and eyonis® HCC, aimed at early diagnosis of primary liver cancer. The remainder will be directed toward general corporate expenses and to support the company’s operations through 2026.

Chief Executive Officer Fredrik Brag emphasized that the transaction also reinforces the company’s ability to pursue distribution agreements and unlock the value of its broader Software as a Medical Device (SaMD) platform. He added that the funding provides “solid financial resources needed for the commercial launch” in the U.S. while enabling sustained development of Median Technologies’ pipeline.

This capital raise marks a strategic inflection point for the France-based health technology firm, as it moves from primarily research and development activity toward regulatory clearance and commercial execution.

What does the warrant structure imply for future fundraising capacity and share dilution?

Each ABSA unit comprised one new ordinary share and a warrant entitling the holder to purchase additional shares under favorable terms. Specifically, two warrants may be exercised to acquire three new ordinary shares at an exercise price of €2.39 per share, reflecting a theoretical value of €0.90 per share based on a 76 percent volatility assumption via the Black-Scholes model. The warrants will expire 30 months after issuance, with a maturity date of February 5, 2028.

If fully exercised, the warrants could generate an additional €51.7 million in gross proceeds, strengthening the company’s liquidity without the need for further debt. Institutional investors have interpreted this optionality positively, viewing it as a mechanism for future capitalization that maintains shareholder alignment while offering upside to current participants.

The warrants are scheduled to begin trading on August 5, 2025, under the ISIN code FR0014011D04, concurrent with the trading debut of the new ordinary shares under the existing ALMDT ticker on Euronext Growth Paris.

What does investor participation in the offering suggest about sentiment around Median Technologies?

The offering attracted broad interest from institutional and qualified investors across multiple geographies. According to disclosures, participants included major life sciences and technology investors based in Sweden, France, the United Kingdom, Germany, and the United States. Among these were Celestial Successor Fund LP, Lion Point Life Science Partners, and Herald Investment Trust.

Institutional investors accounted for 35 percent of the final allocation via a global placement structure that complied with U.S. and EU securities laws. Existing shareholders received 64 percent of the ABSA units through a five-day priority subscription window. Only 2 percent of the offering was allocated through the French public subscription tranche.

The level of participation, particularly from new international investors, signals growing market confidence in the company’s AI-driven approach to cancer diagnostics and its progress toward commercialization. Analysts have noted that institutional backers appear to view Median Technologies as a viable platform player in the digital health segment, rather than a single-product venture.

How does the capital raise affect Median Technologies’ ownership structure and trading profile?

The post-offering ownership structure reflects a significant increase in free float, now accounting for approximately 78.7 percent of total shares outstanding. Prior to the capital raise, the free float stood at 69.7 percent. Celestial Successor Fund LP notably expanded its position from 6.6 percent to 7.5 percent, while longer-standing investors such as Canon Inc. and Furui Medical Science Company Luxembourg saw their stakes diluted on a relative basis.

The total number of outstanding shares has risen from 19.45 million to 33.87 million. Median Technologies confirmed that the new shares are of the same class and fully fungible with existing stock. This increased liquidity is expected to improve visibility among institutional investors, particularly in France and across the European Growth Markets.

While dilution remains a concern for some retail shareholders who did not participate in the raise, analysts have noted that the deal terms were designed to preserve long-term upside while aligning with the company’s medium-term funding needs.

What impact will the capital raise have on access to the EIB financing facility?

The €23.9 million capital raise fulfills a key precondition for accessing the EIB loan facility announced on July 11, 2025. The first €19 million tranche is expected to be disbursed shortly, supplementing the equity raise and further enhancing the company’s operational flexibility. The EIB facility, which totals €37.5 million, provides a mix of low-cost debt capital and milestone-based access, enabling the oncology-focused software firm to pursue regulatory filings, expand its clinical trial footprint, and scale distribution channels without additional equity dilution in the near term.

This financial structure reflects a growing trend in Europe’s healthcare sector, where hybrid funding models—blending institutional equity with pan-European financial support—are becoming more common for growth-stage medtech firms.

What are the key risks to Median Technologies’ growth trajectory despite its strengthened balance sheet?

Despite a successful funding round and growing investor interest, Median Technologies faces a range of risks as it transitions into a commercial-stage business. These include regulatory approval timelines in the U.S. and Europe, pricing and reimbursement uncertainty for its AI-driven SaMD products, and technological competition in the early cancer detection space.

Share price volatility and warrant-related overhang may also affect the company’s capital markets performance over the coming quarters. Median Technologies addressed these concerns in its 2024 Annual Financial Report, specifically under Section P: Specific Risk Factors.

Analysts caution that successful commercialization of eyonis® LCS will depend on execution in clinical validation, sales partner alignment, and adoption by U.S. health systems—each of which introduces operational complexity.

What is the future outlook for Median Technologies following this capital increase?

With a reinforced balance sheet, growing institutional support, and an activated EIB loan facility, Median Technologies is better positioned to meet its strategic objectives in 2025 and 2026. The company’s focus remains on commercializing its AI-powered diagnostic solutions, particularly in high-burden disease areas such as lung and liver cancer.

Analysts expect further updates on FDA submissions, European expansion plans, and potential strategic partnerships over the coming quarters. Median Technologies’ dual-track business model—combining iCRO imaging services with the eyonis® SaMD suite—gives it both recurring service revenues and scalable software upside. This hybrid positioning could make the company an attractive candidate for licensing agreements or even future M&A activity.

As the global oncology diagnostics market increasingly embraces AI-driven tools for early detection, Median Technologies appears well placed to compete, provided it can navigate regulatory and commercialization milestones over the next 18–24 months.